FDA suffers setback in pedigree suit brought by secondary wholesaler
It's unclear whether FDA will seek further review by the U.S. Supreme Court.
The U.S. Court of Appeals for the Second Circuit has affirmed the granting of a preliminary injunction by the District Court in the RxUSA et al v. FDA suit. The suit was filed by a secondary wholesaler, RxUSA, and others against the Food & Drug Administration over its requirement for drug pedigree. It's not clear yet whether FDA will seek further review by the U.S. Supreme Court. Even if FDA chooses not to go that route, the case still has to be litigated. Lawyers for RxUSA are preparing for discovery and trial.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
How PBMs Impede Pharmacists’ Ability to Perform Clinical Services | APhA 2025
March 31st 2025Antonio Ciaccia, President of 3 Axis Advisors, led a discussion on pharmacy benefit manager reform and how the inability to pass legislation has led to increased financial hardships in community pharmacy.
